Compare Docusign Inc (DOCU) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Novo Nordisk A/S — how do they compare? Docusign Inc trades at $71.08 (market cap $13.35B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 12.4× Docusign Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Docusign Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and Novo Nordisk A/S for 116 Days on average.
| DOCU | NVO | |
|---|---|---|
Market Cap | $13.35B | $165.31B |
Volume | 3,158,858 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $73.14 | $63.98 |
52-Week Low | $41.75 | $35.29 |
Typical Hold Time | 71 Days | 116 Days |
Enterprise Value | $12.76B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $71.43, up 3.67% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $2.98B in 2025, with net income surging to $1.07B, though cash flow turned negative. The stock is supported by AI-driven IAM adoption and leadership in signing workflow software, as noted in recent news.
Outlook is mixed: growth from AI and market position offers upside, but high valuation (P/E 43.55), insider selling, and slowing revenue growth pose risks. Analyst consensus is cautious with a $68.75 target below current price, suggesting limited near-term gains amid competitive and execution challenges.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
